Skip to main content

FDA Approvals

Payers' Guide, FDA Approvals

The Health Burden of Multiple Myeloma: Subcutaneous Velcade a New, Convenient Route of Administration Option

Rhonda Williams, Medical Writer

Payers' Guide, FDA Approvals

Kyprolis: A New Treatment Option for Patients with Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib and an Immunomodulatory Agent

Lynne Lederman, PhD, Medical Writer

Payers' Guide, FDA Approvals

Jentadueto: A New Oral Antihyperglycemic Combination Therapy for Patients with Type 2 Diabetes

Wayne Kuznar, Medical Writer

Payers' Guide, FDA Approvals

Abraxane Receives New Indication for Locally Advanced or Metastatic Non–Small-Cell Lung Cancer When Curative Surgery or Radiation Therapy Is Not an Option

Lynne Lederman, PhD

FDA Approvals, Payers' Guide

FDA Approvals of Brand-Name Prescription Drugs in 2012

FDA Approvals, Payers' Guide

Foreword: The Fourth Annual Payers’ Guide to New FDA Approvals

FDA Approvals, Payers' Guide

Introduction: New FDA Drug Approvals in 2012: A 15-Year High

Gary M. Owens, MD

Ponatinib: New Option for the Treatment of Adults with CML or Ph+ ALL that Is Resistant or Intolerant to Previous Therapy with Tyrosine Kinase Inhibitors

Lynne Lederman, PhD

Qsymia: Combination Oral Therapy a New Weight-Loss Option for Obese or Overweight Patients

... .. ...., ....

Belviq: A New Prescription Weight-Loss Treatment for Overweight or Obese Patients

... .. ...., ....

Page 49 of 53
Results 481 - 490 of 525